Compare Roundhill Magnificent Seven ETF (MAGS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Novartis AG — how do they compare? Roundhill Magnificent Seven ETF trades at $67.07, while Novartis AG trades at $154.62 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals.
| MAGS | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.94 | $168.62 |
52-Week Low | $55.39 | $113.50 |
Market Cap | — | $290.25B |
Enterprise Value | — | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS, the Roundhill Magnificent Seven ETF, trades at $66.93, showing minimal daily movement with a neutral technical signal. It holds an equal-weight basket of seven mega-cap tech stocks, benefiting from AI-driven market trends but facing concentration risks. Recent news highlights AI spending shifts and broadening market gains beyond chipmakers.
The ETF's outlook hinges on AI adoption and hyperscaler performance, with potential from compressed valuations, but risks include overconcentration and high expectations. Institutional interest remains strong, though analyst views are mixed amid sector rotation.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
